From: Cost-effectiveness of preemptive skin treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer in Japan
Total
Cost JPY (USD)
Incremental
QALYs
Incremental QALYs
ICER JPY/QALYs
(USD/QALYs)
Reactive
39,809
0.6726
(365.2)
Preemptive
45,109
5300
0.6755
0.0029
1,843,395
(413.8)
(48.6)
(16,912)